Wave Life Sciences Ltd. Ordinary Shares (WVE)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 317
- Market Cap
- $1.1B
About Wave Life Sciences Ltd. Ordinary Shares
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
SentiSense also tracks daily options readings for Wave Life Sciences Ltd. Ordinary Shares: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Wave Life Sciences Ltd. Ordinary Shares stock analysis, sentiment tracking, and market intelligence on SentiSense.